Asset Details
Do you wish to reserve the book?
1186 ASKG193, a novel masked CD19 T-cell engager exhibited potency and expanded safety
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
1186 ASKG193, a novel masked CD19 T-cell engager exhibited potency and expanded safety
Do you wish to request the book?
1186 ASKG193, a novel masked CD19 T-cell engager exhibited potency and expanded safety
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
1186 ASKG193, a novel masked CD19 T-cell engager exhibited potency and expanded safety
2025
Overview
BackgroundT-cell engager (TCE) is a potent antibody-based molecule that induced T cell-mediated killing by bridging CD3 and tumor-associated antigen(TAA). However, therapeutic potential has been significantly limited due to its poor pharmacokinetic, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).MethodsTo improve the developability of TCEs, a proprietary TCE prodrug platform was established to achieve its overarching objective of modulating immune reactions at a disease site in a selective and controlled manner. Several prodrug-TCE molecules were designed and tested, including binding, cytotoxicity, and cytokine release assays in vitro, as well as safety and efficacy studies in vivo.ResultsHere, we reported ASKG193, a next generation CD19-CD3 TCE, with a masking strategy to attenuate off-target toxicity, extend half-life and improve systemic exposure. The non-activated ASKG193 showed no activity, while the activated form demonstrated >100 folds attenuation in vitro compared to a CD19 Bi-specific T-cell engager (BiTE). In ex vivo B-cell depletion assay, ASKG193 retained potent cytolytic activity comparable to the CD19 BiTE molecule. In addition, ASKG193 was well tolerated in vivo.ConclusionsIn summary, the masked CD19 TCE, ASKG193, exhibited superior anti-tumor efficacy, prolonged half-life, and a significantly improved safety profile. Our data demonstrated that the ASKG193 has the potential to substantially broaden the therapeutic window for CD19-targeted immunotherapies.
Publisher
BMJ Publishing Group LTD
Subject
